{"nctId":"NCT04280705","briefTitle":"Adaptive COVID-19 Treatment Trial (ACTT)","startDateStruct":{"date":"2020-02-21","type":"ACTUAL"},"conditions":["COVID-19"],"count":1062,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]},{"label":"Remdesivir","type":"EXPERIMENTAL","interventionNames":["Drug: Remdesivir"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Remdesivir","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Admitted to a hospital with symptoms suggestive of COVID-19 infection.\n2. Subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures.\n3. Subject (or legally authorized representative) understands and agrees to comply with planned study procedures.\n4. Male or non-pregnant female adult \\> / = 18 years of age at time of enrollment.\n5. Has laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction (PCR) or other commercial or public health assay in any specimen, as documented by either or the following:\n\n   1. PCR positive in sample collected \\< 72 hours prior to randomization; OR\n\n      Exclusion Criteria:\n   2. PCR positive in sample collected \\>/= 72 hours prior to randomization, documented inability to obtain a repeat sample (e.g. due to lack of testing supplies, limited testing capacity, results taking \\>24 hours, etc.) AND progressive disease suggestive of ongoing SARS-CoV-2 infection.\n6. Illness of any duration, and at least one of the following:\n\n   1. Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.), OR\n   2. SpO2 \\< / = 94% on room air, OR\n   3. Requiring supplemental oxygen, OR\n   4. Requiring mechanical ventilation.\n7. Women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through Day 29.\n8. Agrees to not participate in another clinical trial for the treatment of COVID-19 or SARS-CoV-2 through Day 29.\n\nExclusion Criteria:\n\n1. Alanine Transaminase (ALT) or Aspartate Transaminase (AST) \\> 5 times the upper limit of normal.\n2. Estimated glomerular filtration rate (eGFR) \\< 30 ml/min (including patients receiving hemodialysis or hemofiltration).\n3. Pregnancy or breast feeding.\n4. Anticipated discharge from the hospital or transfer to another hospital which is not a study site within 72 hours.\n5. Allergy to any study medication.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Recovery","description":"Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the ordinal scale: 1) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Not hospitalized, no limitations on activities.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Alanine Transaminase (ALT)","description":"Blood to evaluate ALT was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":"88"},{"groupId":"OG001","value":"2.9","spread":"31.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.1","spread":"70.6"},{"groupId":"OG001","value":"10.8","spread":"55.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.2","spread":"79.7"},{"groupId":"OG001","value":"8.9","spread":"54.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.7","spread":"89.8"},{"groupId":"OG001","value":"3.4","spread":"48.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.1","spread":"110.1"},{"groupId":"OG001","value":"1.7","spread":"47.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":"62.2"},{"groupId":"OG001","value":"-6.8","spread":"43.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Aspartate Transaminase (AST)","description":"Blood to evaluate AST was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.7","spread":"90.7"},{"groupId":"OG001","value":"-2.0","spread":"29.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":"66.2"},{"groupId":"OG001","value":"6.0","spread":"58.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1","spread":"114.6"},{"groupId":"OG001","value":"1.1","spread":"55.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5","spread":"78.8"},{"groupId":"OG001","value":"-0.3","spread":"51.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":"73.0"},{"groupId":"OG001","value":"-2.3","spread":"60.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.4","spread":"47.2"},{"groupId":"OG001","value":"-14.0","spread":"52.2"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Creatinine","description":"Blood to evaluate serum creatinine was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.037","spread":"0.517"},{"groupId":"OG001","value":"0.038","spread":"0.569"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.695","spread":"17.552"},{"groupId":"OG001","value":"0.075","spread":"0.762"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.882","spread":"19.637"},{"groupId":"OG001","value":"0.158","spread":"0.951"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.173","spread":"15.440"},{"groupId":"OG001","value":"0.236","spread":"1.057"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.239","spread":"22.755"},{"groupId":"OG001","value":"0.319","spread":"2.147"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.863","spread":"26.093"},{"groupId":"OG001","value":"0.075","spread":"0.644"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Glucose","description":"Blood to evaluate serum glucose was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"53.4"},{"groupId":"OG001","value":"-3.0","spread":"49.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"60.2"},{"groupId":"OG001","value":"2.1","spread":"63.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"73.3"},{"groupId":"OG001","value":"3.2","spread":"68.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"70.1"},{"groupId":"OG001","value":"-0.1","spread":"77.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.8","spread":"64.4"},{"groupId":"OG001","value":"-2.9","spread":"75.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.5","spread":"96.8"},{"groupId":"OG001","value":"-11.7","spread":"75.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hemoglobin","description":"Blood to evaluate hemoglobin was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.52","spread":"1.10"},{"groupId":"OG001","value":"-0.69","spread":"5.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.83","spread":"1.22"},{"groupId":"OG001","value":"-0.99","spread":"5.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.22","spread":"1.42"},{"groupId":"OG001","value":"-0.49","spread":"6.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.66","spread":"1.67"},{"groupId":"OG001","value":"-1.29","spread":"1.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.51","spread":"2.02"},{"groupId":"OG001","value":"-1.02","spread":"3.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.02","spread":"2.38"},{"groupId":"OG001","value":"-1.21","spread":"7.91"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Platelets","description":"Blood to evaluate platelets was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.3","spread":"60.0"},{"groupId":"OG001","value":"46.0","spread":"62.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.5","spread":"100.5"},{"groupId":"OG001","value":"90.1","spread":"99.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"111.8","spread":"137.4"},{"groupId":"OG001","value":"130.8","spread":"128.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109.3","spread":"149.3"},{"groupId":"OG001","value":"101.0","spread":"145.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.5","spread":"154.2"},{"groupId":"OG001","value":"71.1","spread":"133.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.7","spread":"124.2"},{"groupId":"OG001","value":"39.6","spread":"107.4"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Prothrombin Time (PT)","description":"Blood to evaluate PT was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.18","spread":"4.28"},{"groupId":"OG001","value":"0.44","spread":"5.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.30","spread":"4.72"},{"groupId":"OG001","value":"1.15","spread":"5.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"2.59"},{"groupId":"OG001","value":"1.43","spread":"3.89"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.86","spread":"7.85"},{"groupId":"OG001","value":"1.88","spread":"5.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.34","spread":"4.33"},{"groupId":"OG001","value":"-0.03","spread":"4.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.28","spread":"3.20"},{"groupId":"OG001","value":"-0.63","spread":"3.37"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Bilirubin","description":"Blood to evaluate total bilirubin was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.08","spread":"1.25"},{"groupId":"OG001","value":"-0.04","spread":"0.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.58","spread":"4.13"},{"groupId":"OG001","value":"-0.03","spread":"1.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":"2.56"},{"groupId":"OG001","value":"0.01","spread":"1.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.23","spread":"2.79"},{"groupId":"OG001","value":"0.07","spread":"1.48"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"1.80"},{"groupId":"OG001","value":"0.09","spread":"1.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.17","spread":"1.65"},{"groupId":"OG001","value":"-0.12","spread":"1.77"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in White Blood Cell Count (WBC)","description":"Blood to evaluate WBC was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.691","spread":"424.837"},{"groupId":"OG001","value":"-18.970","spread":"301.944"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.886","spread":"566.175"},{"groupId":"OG001","value":"-28.209","spread":"412.615"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.223","spread":"479.095"},{"groupId":"OG001","value":"-45.997","spread":"602.461"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.967","spread":"16.042"},{"groupId":"OG001","value":"-34.702","spread":"574.065"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.311","spread":"620.551"},{"groupId":"OG001","value":"-70.884","spread":"600.011"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.898","spread":"17.801"},{"groupId":"OG001","value":"0.251","spread":"3.987"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Neutrophils","description":"Blood to evaluate neutrophils was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.429","spread":"260.345"},{"groupId":"OG001","value":"-8.093","spread":"135.068"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.177","spread":"362.782"},{"groupId":"OG001","value":"-15.067","spread":"216.532"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.916","spread":"305.321"},{"groupId":"OG001","value":"-28.179","spread":"365.099"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.010","spread":"27.502"},{"groupId":"OG001","value":"-21.773","spread":"354.025"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.024","spread":"389.093"},{"groupId":"OG001","value":"-39.988","spread":"333.088"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.269","spread":"7.160"},{"groupId":"OG001","value":"-0.840","spread":"3.666"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Lymphocytes","description":"Blood to evaluate lymphocytes was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.883","spread":"118.740"},{"groupId":"OG001","value":"-7.847","spread":"131.548"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.064","spread":"141.580"},{"groupId":"OG001","value":"-11.723","spread":"167.428"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.006","spread":"137.149"},{"groupId":"OG001","value":"-15.455","spread":"194.111"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.393","spread":"1.371"},{"groupId":"OG001","value":"-12.016","spread":"183.060"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.793","spread":"159.583"},{"groupId":"OG001","value":"-23.836","spread":"218.653"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.668","spread":"1.406"},{"groupId":"OG001","value":"0.743","spread":"0.664"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Monocytes","description":"Blood to evaluate monocytes was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.448","spread":"41.304"},{"groupId":"OG001","value":"-2.940","spread":"46.752"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.498","spread":"57.686"},{"groupId":"OG001","value":"-2.628","spread":"39.329"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.324","spread":"36.626"},{"groupId":"OG001","value":"-3.645","spread":"48.636"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.383","spread":"0.744"},{"groupId":"OG001","value":"-2.539","spread":"43.454"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.475","spread":"69.019"},{"groupId":"OG001","value":"-8.738","spread":"74.365"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.125","spread":"0.485"},{"groupId":"OG001","value":"0.117","spread":"0.340"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Basophils","description":"Blood to evaluate basophils was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.020","spread":"0.257"},{"groupId":"OG001","value":"0.005","spread":"0.043"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.038","spread":"0.501"},{"groupId":"OG001","value":"0.005","spread":"0.370"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.196","spread":"3.132"},{"groupId":"OG001","value":"0.005","spread":"0.368"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.024","spread":"0.042"},{"groupId":"OG001","value":"0.028","spread":"0.053"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.158","spread":"1.913"},{"groupId":"OG001","value":"-0.058","spread":"1.028"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.040","spread":"0.073"},{"groupId":"OG001","value":"0.029","spread":"0.054"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Eosinophils","description":"Blood to evaluate eosinophils was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.634","spread":"10.614"},{"groupId":"OG001","value":"0.016","spread":"0.727"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.666","spread":"11.977"},{"groupId":"OG001","value":"-0.066","spread":"2.807"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.596","spread":"8.875"},{"groupId":"OG001","value":"-0.221","spread":"4.108"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.093","spread":"0.190"},{"groupId":"OG001","value":"-0.088","spread":"2.973"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.992","spread":"20.365"},{"groupId":"OG001","value":"-0.420","spread":"5.378"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.241","spread":"0.324"},{"groupId":"OG001","value":"0.211","spread":"0.267"}]}]}]},{"type":"SECONDARY","title":"Change in National Early Warning Score (NEWS) From Baseline","description":"The NEW score has demonstrated an ability to discriminate patients at risk of poor outcomes. This score is based on 7 clinical parameters (respiration rate, oxygen saturation, any supplemental oxygen, temperature, systolic blood pressure, heart rate, level of consciousness). The NEW Score is being used as an efficacy measure. The minimum score is 0, representing the better outcome, and the maximum value is 19, representing the worse outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"2.8"},{"groupId":"OG001","value":"-0.3","spread":"2.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"3.3"},{"groupId":"OG001","value":"-0.4","spread":"2.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"3.8"},{"groupId":"OG001","value":"-0.5","spread":"3.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"4.1"},{"groupId":"OG001","value":"-0.5","spread":"3.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"4.2"},{"groupId":"OG001","value":"-1.7","spread":"3.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"4.0"},{"groupId":"OG001","value":"-1.7","spread":"4.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","spread":"4.0"},{"groupId":"OG001","value":"-3.3","spread":"3.2"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 1","description":"The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 3","description":"The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 5","description":"The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 8","description":"The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 11","description":"The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 15","description":"The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 22","description":"The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants at Each Clinical Status Using Ordinal Scale at Day 29","description":"The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reporting Grade 3 and 4 Clinical and/or Laboratory Adverse Events (AEs)","description":"Grade 3 AEs are defined as events that interrupt usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Severe events are usually incapacitating. Grade 4 AEs are defined as events that are potentially life threatening.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"51","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reporting Serious Adverse Events (SAEs)","description":"An SAE is defined as an AE or suspected adverse reaction is considered serious if, in the view of either the investigator or the sponsor, it results in death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Discontinued or Temporarily Suspended From Investigational Therapeutics","description":"Participants may have been discontinued from investigational therapeutics due to discharge or death. The halting or slowing of the infusion for any reason was collected, as was missed doses in the series of 10 doses.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Hospitalization","description":"Duration of hospitalization was determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of New Non-invasive Ventilation or High Flow Oxygen Use","description":"Duration of new non-invasive ventilation or high flow oxygen use was measured in days among participants who were not on non-invasive ventilation or high-flow oxygen use at baseline, determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of New Oxygen Use","description":"Duration of new oxygen use was measured in days among participants who were not on oxygen at baseline, determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die\n\n.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use","description":"Duration of new ventilator or ECMO use was measured in days among participants who were not on a ventilator or ECMO at baseline, determined two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"21.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Requiring New Non-invasive Ventilation or High-flow Oxygen Use","description":"New non-invasive ventilation or high-flow oxygen use was determined as the percentage of subject not on non-invasive ventilation or high-flow oxygen at baseline.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Requiring New Oxygen Use","description":"The percentage of participants requiring new oxygen use was determined as the percentage of participants not requiring oxygen at baseline","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Requiring New Ventilator or Extracorporeal Membrane Oxygenation (ECMO) Use","description":"The percentage of participants requiring new ventilator or ECMO use was determined as the percentage not on a ventilator or ECMO at baseline","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change in the Ordinal Scale","description":"The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities. A positive change indicates a worsening and a negative change is an improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.6"},{"groupId":"OG001","value":"0.1","spread":"0.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"0.9"},{"groupId":"OG001","value":"0.0","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.1"},{"groupId":"OG001","value":"-0.2","spread":"1.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.3"},{"groupId":"OG001","value":"-0.3","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"2.3"},{"groupId":"OG001","value":"-1.9","spread":"2.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":"2.5"},{"groupId":"OG001","value":"-2.4","spread":"2.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"2.6"},{"groupId":"OG001","value":"-2.7","spread":"2.3"}]}]}]},{"type":"SECONDARY","title":"14-day Participant Mortality","description":"The mortality rate was determined as the proportion of participants who died by study Day 15.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.12","spread":null},{"groupId":"OG001","value":"0.07","spread":null}]}]}]},{"type":"SECONDARY","title":"29-day Participant Mortality","description":"The mortality rate was determined as the proportion of participants who died by study Day 29.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":null},{"groupId":"OG001","value":"0.11","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to an Improvement by at Least One Category Using an Ordinal Scale","description":"The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 8) Death; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 5) Hospitalized, requiring supplemental oxygen; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 1) Not hospitalized, no limitations on activities. Time to improvement by at least one category was determined for each participant","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to an Improvement of at Least Two Categories Using an Ordinal Scale","description":"The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities. Time to improvement by at least two categories was determined for each participant","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Discharge or to a NEWS of 2 or Less and Maintained for 24 Hours, Whichever Occurs First","description":"The NEW score has demonstrated an ability to discriminate patients at risk of poor outcomes. This score is based on 7 clinical parameters (respiration rate, oxygen saturation, any supplemental oxygen, temperature, systolic blood pressure, heart rate, level of consciousness). The NEW Score is being used as an efficacy measure. The minimum score is 0, representing the better outcome, and the maximum value is 19, representing the worse outcome. The time to discharge or a NEWS of less than or equal to 2 was determined for each participant.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"PRIMARY","title":"Time to Recovery by Race","description":"Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the ordinal scale: 1) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Not hospitalized, no limitations on activities.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.0","spread":null},{"groupId":"OG001","value":"11.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","spread":null},{"groupId":"OG001","value":"10.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","spread":null},{"groupId":"OG001","value":"9.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","spread":null},{"groupId":"OG001","value":"9.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Time to Recovery by Ethnicity","description":"Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the ordinal scale: 1) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Not hospitalized, no limitations on activities.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","spread":null},{"groupId":"OG001","value":"10.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","spread":null},{"groupId":"OG001","value":"10.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Time to Recovery by Sex","description":"Day of recovery is defined as the first day on which the subject satisfies one of the following three categories from the ordinal scale: 1) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Not hospitalized, no limitations on activities.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","spread":null},{"groupId":"OG001","value":"9.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","spread":null},{"groupId":"OG001","value":"10.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":163,"n":516},"commonTop":["Glomerular filtration rate decreased","Haemoglobin decreased","Lymphocyte count decreased","Anaemia","Pyrexia"]}}}